| Old Articles: <Older 6691-6700 Newer> |
|---|
 |
The Motley Fool
September 16, 2010
Seth Jayson |
Will Almost Family Whiff on Revenues Next Quarter? For the last fully reported fiscal quarter, Almost Family's year-over-year revenue grew 14.8%, and its AR grew 7.8%.   |
The Motley Fool
September 16, 2010
Brian Orelli |
Abbott's Product Line May Get Thinner Not that it needs the obesity drug. |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
The Motley Fool
September 15, 2010
Bruce V. Bigelow |
In Appeal to Cypress Bio Stockholders, Ramius Raises Buyout Offer The battle for control is heating up. |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
September 15, 2010
Seth Jayson |
Will LabCorp Fumble Next Quarter? There's no foolproof way to know the future for Laboratory Corp. of America Holdings or any other company. |
The Motley Fool
September 14, 2010
Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. |
The Motley Fool
September 14, 2010
Brian Orelli |
This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
September 13, 2010
Brian Orelli |
When All Else Fails, Sell! Genzyme has no other choice. |
| <Older 6691-6700 Newer> Return to current articles. |
